Observational studyJAMA oncology2016
Analysis of Body Mass Index and Mortality in Patients With Colorectal Cancer Using Causal Diagrams.
Observational study in JAMA oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Body mass index, adjuvant chemotherapy, toxicity, and survival in non-metastatic colorectal cancer: an individual participant data meta-analysis (OCTOPUS).British journal of cancer · 2026Pooled it
- Body mass index and cancer survival: a meta-analysis of cohort studies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Pooled it
- Evaluating the influence of the obesity paradox on survival outcomes in patients being treated surgically for rectal cancer-a systematic review and meta-analysis.International journal of colorectal disease · 2025Pooled it
- Trial
- Methodological considerations for disentangling a risk factor's influence on disease incidence versus postdiagnosis survival: The example of obesity and breast and colorectal cancer mortality in the Women's Health Initiative.International journal of cancer · 2017Trial
- Underweight Versus Obesity and Gastrointestinal Cancer Mortality in Type 2 Diabetes: A Nationwide Cohort Study.Journal of cachexia, sarcopenia and muscle · 2026Article
- Body Mass Index at Diagnosis, Prediagnostic Weight Loss, and Survival in Colorectal Cancer.JAMA network open · 2026Article
- Survival Outcomes of Patients With Colorectal Cancer After Primary Surgery: A Population-Based Study in Hainan, China.Cancer medicine · 2026Article
- Association between cumulative lifetime exposure to reproductive hormones and tumor-infiltrating lymphocytes, CD4 +, and CD8 + T cells among women with breast cancer.Cancer immunology, immunotherapy : CII · 2026Article
- Body mass index and colorectal cancer recurrence and mortality: A nationwide cohort study in Denmark.International journal of cancer · 2026Article
- Obesity, survival, and chemotherapy outcomes in stage IV colorectal cancer: a retrospective study.BMC cancer · 2026Article
- Circulating fatty acid binding protein 4 (FABP-4) concentrations and mortality in individuals with colorectal cancer in the European Prospective Investigation into Cancer and Nutrition study.International journal of cancer · 2026Article
- Tumor Characteristics and Survival Predictors in Patients With Colorectal Cancer: A Lebanese Single-Center Experience.Clinical Medicine Insights. Oncology · 2026Article
- Development and validation of a pre-chemotherapy nomogram integrating systemic immune-inflammation index and prognostic nutritional index to predict severe adjuvant toxicity in colorectal cancer.Frontiers in oncology · 2026Article
- Influencing factors of prognosis in HIV infected individuals undergoing surgical treatment for colorectal cancer.Frontiers in oncology · 2026Article
- Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside.Nature communications · 2025Review
- Identification of prognostic indicators for early recurrence of gastric cancer following laparoscopic gastrectomy.BMC surgery · 2025Article
- Metformin and weight loss medication impact on survival outcomes in older women with obesity-related cancers.Scientific reports · 2025Article
- The role of adipogenic niche resident cells in colorectal cancer progression in relation to obesity.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- Body Composition Analysis in Metastatic Non-Small-Cell Lung Cancer: Depicting Sarcopenia in Portuguese Tertiary Care.Cancers · 2025Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
importancePhysicians and investigators have sought to determine the relationship between body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]) and colorectal cancer (CRC) outcomes, but methodologic limitations including sampling selection bias, reverse causality, and collider bias have prevented the ability to draw definitive conclusions.
objectiveTo evaluate the association of BMI at the time of, and following, colorectal cancer (CRC) diagnosis with mortality in a complete population using causal diagrams. DESIGN, SETTING, AND
participantsThis retrospective observational study with prospectively collected data included a cohort of 3408 men and women, ages 18 to 80 years, from the Kaiser Permanente Northern California population, who were diagnosed with stage I to III CRC between 2006 and 2011 and who also had surgery. EXPOSURES: Body mass index at diagnosis and 15 months following diagnosis. MAIN OUTCOMES AND MEASURES: Hazard ratios (HRs) for all-cause mortality and CRC-specific mortality compared with normal-weight patients, adjusted for sociodemographics, disease severity, treatment, and prediagnosis BMI.
resultsThis study investigated a cohort of 3408 men and women ages 18 to 80 years diagnosed with stage I to III CRC between 2006 and 2011 who also had surgery. At-diagnosis BMI was associated with all-cause mortality in a nonlinear fashion, with patients who were underweight (BMI <18.5; HR, 2.65; 95% CI, 1.63-4.31) and patients who were class II or III obese (BMI ≥35; HR, 1.33; 95% CI, 0.89-1.98) exhibiting elevated mortality risks, compared with patients who were low-normal weight (BMI 18.5 to <23). In contrast, patients who were high-normal weight (BMI 23 to <25; HR, 0.77; 95% CI, 0.56-1.06), low-overweight (BMI 25 to <28; HR, 0.75; 95% CI, 0.55-1.04), and high-overweight (BMI 28 to <30; HR, 0.52; 95% CI, 0.35-0.77) had lower mortality risks, and patients who were class I obese (BMI 30 to <35) showed no difference in risk. Spline analysis confirmed a U-shaped relationship in participants with lowest mortality at a BMI of 28. Associations with CRC-specific mortality were similar. Associations of postdiagnosis BMI and mortality were also similar, but patients who were class I obese had significantly lower all-cause and cancer-specific mortality risks. CONCLUSIONS AND RELEVANCE: In this study, body mass index at the time of diagnosis and following diagnosis of CRC was associated with mortality risk. Though evidence shows that exercise in patients with cancer should be encouraged, findings suggest that recommendations for weight loss in the immediate postdiagnosis period among patients with CRC who are overweight may be unwarranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.